First enzyme-targeting drug reverses damage in metabolic fatty liver disease
by University of California – San Diego edited by Gaby Clark, reviewed by Robert Egan Credit: CC0 Public Domain Researchers at the University of California San Diego School of Medicine have identified a new investigational drug that shows promise in treating metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease linked to obesity and type 2 […]
First enzyme-targeting drug reverses damage in metabolic fatty liver disease Read More »
